Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Bacitracin
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Bacitracin

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (932 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140)

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Bacitracin Zinc Complex; Zinc Bacitracin; Bacitracin, Zinc; Bacitracin Zinc; Zinc, Bacitracin; Ak-Tracin; Ak Tracin; Baci-IM.

Where it fits in the MeSH classification

Broader topics
Peptides, Cyclic

Research landscape

PubMed indexes 2,729 records tagged with the MeSH heading “Bacitracin” (counts retrieved 2026-10-31). 163 of them (6.0%) were published from 2020 onward, and the busiest period so far is through 1999 with 1,998 records.

Reviews account for 96 records (3.5%) and meta-analyses for 2. Randomized controlled trials number 94 (3.4%) as a share of all records on the topic.

PubMed records by publication periodthrough 1999: 1,998 records; 2000-2009: 299 records; 2010-2019: 269 records; 2020 onward: 163 records1,998through 19992992000-20092692010-20191632020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19991,998
2000-2009299
2010-2019269
2020 onward163
Share of records by publication typeReviews: 3.5 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 3.4 percentReviews3.5% (96)Meta-analyses0.1% (2)Randomized controlled trials3.4% (94)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 2,729 PubMed records
TypeRecordsShare
Reviews963.5%
Meta-analyses20.1%
Randomized controlled trials943.4%

Method: PubMed query "Bacitracin"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Tannins and Bacitracin Differentially Modulate Gut Microbiota of Broiler Chickens
Díaz Carrasco JM, Redondo EA, Pin Viso ND, Redondo LM, Farber MD, Fernández Miyakawa ME
2018Research article
Design not recorded in structured metadata
82cc by
PMID 29682522 · DOI · PMC5841071
Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria
Wassmann CS, Højrup P, Klitgaard JK
2020Research article
Design not recorded in structured metadata
66cc by
PMID 32139776 · DOI · PMC7057955
Characterization of genes encoding for acquired bacitracin resistance in Clostridium perfringens
Charlebois A, Jalbert LA, Harel J, Masson L, Archambault M
2012Research article
Design not recorded in structured metadata
43cc by
PMID 22970221 · DOI · PMC3435297
Paenitracins, a novel family of bacitracin-type nonribosomal peptide antibiotics produced by plant-associated Paenibacillus species
Machushynets NV, Elsayed SS, Du C, Lysenko V, de la Cruz M, Sanchez P, et al.
2026Research article
Design not recorded in structured metadata
0cc by
PMID 41700860 · DOI · PMC13011432

Tannins and Bacitracin Differentially Modulate Gut Microbiota of Broiler Chickens [1]

Research article Díaz Carrasco JM, Redondo EA, Pin Viso ND, Redondo LM, Farber MD, Fernández Miyakawa ME · · 2018 · cited 82 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Antibiotic growth promoters have been used for decades in poultry farming as a tool to maintain bird health and improve growth performance.
Closing excerpt
Different members of these groups have been associated with an improvement of intestinal health and feed efficiency in poultry, suggesting that these bacteria could be associated with productive performance of birds.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (203 words)

Antibiotic growth promoters have been used for decades in poultry farming as a tool to maintain bird health and improve growth performance. Global concern about the recurrent emergence and spreading of antimicrobial resistance is challenging the livestock producers to search for alternatives to feed added antibiotics. The use of phytogenic compounds appears as a feasible option due to their ability to emulate the bioactive properties of antibiotics. However, detailed description about the effects of in-feed antibiotics and alternative natural products on chicken intestinal microbiota is lacking. High-throughput sequencing of 16S rRNA gene was used to study composition of cecal microbiota in broiler chickens supplemented with either bacitracin or a blend of chestnut and quebracho tannins over a 30-day grow-out period. Both tannins and bacitracin had a significant impact on diversity of cecal microbiota. Bacitracin consistently decreased Bifidobacterium while other bacterial groups were affected only at certain times. Tannins-fed chickens showed a drastic decrease in genus Bacteroides while certain members of order Clostridiales mainly belonging to the families Ruminococcaceae and Lachnospiraceae were increased. Different members of these groups have been associated with an improvement of intestinal health and feed efficiency in poultry, suggesting that these bacteria could be associated with productive performance of birds.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29682522 · DOI · PMC5841071

Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria [2]

Research article Wassmann CS, Højrup P, Klitgaard JK · · 2020 · cited 66 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The cannabinoid cannabidiol (CBD) is characterised in this study as a helper compound against resistant bacteria.
Closing excerpt
Based on these observations, the combination of CBD and BAC is suggested to be a putative novel treatment in clinical settings for treatment of infections with antibiotic resistant Gram-positive bacteria.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (200 words)

The cannabinoid cannabidiol (CBD) is characterised in this study as a helper compound against resistant bacteria. CBD potentiates the effect of bacitracin (BAC) against Gram-positive bacteria (Staphylococcus species, Listeria monocytogenes, and Enterococcus faecalis) but appears ineffective against Gram-negative bacteria. CBD reduced the MIC value of BAC by at least 64-fold and the combination yielded an FIC index of 0.5 or below in most Gram-positive bacteria tested. Morphological changes in S. aureus as a result of the combination of CBD and BAC included several septa formations during cell division along with membrane irregularities. Analysis of the muropeptide composition of treated S. aureus indicated no changes in the cell wall composition. However, CBD and BAC treated bacteria did show a decreased rate of autolysis. The bacteria further showed a decreased membrane potential upon treatment with CBD; yet, they did not show any further decrease upon combination treatment. Noticeably, expression of a major cell division regulator gene, ezrA, was reduced two-fold upon combination treatment emphasising the impact of the combination on cell division. Based on these observations, the combination of CBD and BAC is suggested to be a putative novel treatment in clinical settings for treatment of infections with antibiotic resistant Gram-positive bacteria.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32139776 · DOI · PMC7057955

Characterization of genes encoding for acquired bacitracin resistance in Clostridium perfringens [3]

Research article Charlebois A, Jalbert LA, Harel J, Masson L, Archambault M · · 2012 · cited 43 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Phenotypic bacitracin resistance has been reported in Clostridium perfringens.
Closing excerpt
perfringens isolates from turkeys and broiler chickens.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (264 words)

Phenotypic bacitracin resistance has been reported in Clostridium perfringens. However, the genes responsible for the resistance have not yet been characterized. Ninety-nine C. perfringens isolates recovered from broilers and turkeys were tested for phenotypic bacitracin resistance. Bacitracin MIC(90) (>256 µg/ml) was identical for both turkey and chicken isolates; whereas MIC(50) was higher in turkey isolates (6 µg/ml) than in chicken isolates (3 µg/ml). Twenty-four of the 99 isolates showed high-level bacitracin resistance (MIC breakpoint >256 µg/ml) and the genes encoding for this resistance were characterized in C. perfringens c1261_A strain using primer walking. Sequence analysis and percentages of amino acid identity revealed putative genes encoding for both an ABC transporter and an overproduced undecaprenol kinase in C. perfringens c1261_A strain. These two mechanisms were shown to be both encoded by the putative bcrABD operon under the control of a regulatory gene, bcrR. Efflux pump inhibitor thioridazine was shown to increase significantly the susceptibility of strain c1261_A to bacitracin. Upstream and downstream from the bcr cluster was an IS1216-like element, which may play a role in the dissemination of this resistance determinant. Pulsed-field gel electrophoresis with prior double digestion with I-CeuI/MluI enzymes followed by hybridization analyses revealed that the bacitracin resistance genes bcrABDR were located on the chromosome. Semi-quantitative RT-PCR demonstrated that this gene cluster is expressed under bacitracin stress. Microarray analysis revealed the presence of these genes in all bacitracin resistant strains. This study reports the discovery of genes encoding for a putative ABC transporter and an overproduced undecaprenol kinase associated with high-level bacitracin resistance in C. perfringens isolates from turkeys and broiler chickens.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 22970221 · DOI · PMC3435297

Paenitracins, a novel family of bacitracin-type nonribosomal peptide antibiotics produced by plant-associated Paenibacillus species [4]

Research article Machushynets NV, Elsayed SS, Du C, Lysenko V, de la Cruz M, Sanchez P, et al. · · 2026

Abstract reading summary — source excerpts
Opening excerpt
The growing threat of antimicrobial resistance necessitates the discovery of novel antibiotics with activity against drug-resistant pathogens.
Closing excerpt
Our pipeline enables the discovery of novel peptidic natural products to accelerate the prioritization of chemical space for antibiotics.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (265 words)

The growing threat of antimicrobial resistance necessitates the discovery of novel antibiotics with activity against drug-resistant pathogens. Members of the genus Paenibacillus are a rich source of nonribosomal peptides (NRPs), including well-known antibiotics such as polymyxins, paenibacterin, and tridecaptins. Here, we use a targeted mass spectrometry query language (MassQL)-based approach to identify the NRPs produced by a collection of 227 taxonomically diverse plant-associated Paenibacillus strains, providing detailed insights into their NRP-producing potential. Using MassQL to zoom in specifically on NRPs containing basic amino acids, we discovered a novel family of bacitracins, which we designated paenitracins. The paenitracins are the first bacitracin-type peptides reported in Paenibacillus and are distinguished from canonical bacitracins by three previously unseen amino acid substitutions. The paenitracins exhibit potent activity against gram-positive pathogens, including vancomycin-resistant Enterococcus faecium E155. Our work provides a novel metabolomics-guided and genomics-guided workflow for the discovery of bioactive NRPs as a strategy to prioritize natural product chemical space and accelerate antibiotic discovery.IMPORTANCEMembers of the genus Paenibacillus play an important role in soil ecology, producing a range of important nonribosomal peptides (NRPs). A collection of plant-associated Paenibacillus spp. were analyzed for their phylogenetic and metabolic diversity. We developed a novel discovery pipeline that combines feature-based molecular networking with mass spectrometry query language queries to systematically prioritize bioactive NRPs containing basic amino acids. Thus, we provide a comprehensive genus-wide inventory of NRPs produced by Paenibacillus spp. We thereby identified the paenitracins, a new sub-family of bacitracins active against multidrug-resistant gram-positive pathogens. Our pipeline enables the discovery of novel peptidic natural products to accelerate the prioritization of chemical space for antibiotics.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41700860 · DOI · PMC13011432

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Metal binding and structure-activity relationship of the metalloantibiotic peptide bacitracin [5]
    Ming LJ, Epperson JD · J Inorg Biochem · 2002 · cited 110 times (Europe PMC)
  • Research article Structure and function of "metalloantibiotics" [6]
    Ming LJ · Med Res Rev · 2003 · cited 105 times (Europe PMC)
  • Research article Genes involved in bacitracin resistance in Streptococcus mutans [7]
    Tsuda H, Yamashita Y, Shibata Y, Nakano Y, Koga T · Antimicrob Agents Chemother · 2002 · cited 74 times (Europe PMC)
  • Research article MECHANISMS OF ANTIBIOTIC ACTION [8]
    GALE EF · Pharmacol Rev · 1963 · cited 46 times (Europe PMC)
  • Research article Role of two-component systems in the resistance of Staphylococcus aureus to antibacterial agents [9]
    Kawada-Matsuo M, Yoshida Y, Nakamura N, Komatsuzawa H · Virulence · 2011 · cited 39 times (Europe PMC)
  • Research article Bacitracin [10]
    Toscano WA, Storm DR · Pharmacol Ther · 1982 · cited 35 times (Europe PMC)

References

  1. Díaz Carrasco JM, Redondo EA, Pin Viso ND, Redondo LM, Farber MD, Fernández Miyakawa ME. Tannins and Bacitracin Differentially Modulate Gut Microbiota of Broiler Chickens. . 2018. PMID 29682522 · DOI · PMC5841071
  2. Wassmann CS, Højrup P, Klitgaard JK. Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria. . 2020. PMID 32139776 · DOI · PMC7057955
  3. Charlebois A, Jalbert LA, Harel J, Masson L, Archambault M. Characterization of genes encoding for acquired bacitracin resistance in Clostridium perfringens. . 2012. PMID 22970221 · DOI · PMC3435297
  4. Machushynets NV, Elsayed SS, Du C, Lysenko V, de la Cruz M, Sanchez P, et al.. Paenitracins, a novel family of bacitracin-type nonribosomal peptide antibiotics produced by plant-associated Paenibacillus species. . 2026. PMID 41700860 · DOI · PMC13011432
  5. Ming LJ, Epperson JD. Metal binding and structure-activity relationship of the metalloantibiotic peptide bacitracin. J Inorg Biochem. 2002. PMID 12121761 · DOI
  6. Ming LJ. Structure and function of "metalloantibiotics". Med Res Rev. 2003. PMID 12939790 · DOI
  7. Tsuda H, Yamashita Y, Shibata Y, Nakano Y, Koga T. Genes involved in bacitracin resistance in Streptococcus mutans. Antimicrob Agents Chemother. 2002. PMID 12435673 · DOI · PMC132740
  8. GALE EF. MECHANISMS OF ANTIBIOTIC ACTION. Pharmacol Rev. 1963. PMID 14064356 · DOI
  9. Kawada-Matsuo M, Yoshida Y, Nakamura N, Komatsuzawa H. Role of two-component systems in the resistance of Staphylococcus aureus to antibacterial agents. Virulence. 2011. PMID 21921684 · DOI
  10. Toscano WA, Storm DR. Bacitracin. Pharmacol Ther. 1982. PMID 6752975 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • ColistinDrugs and Chemicals
  • CyclosporineDrugs and Chemicals
  • GramicidinDrugs and Chemicals
  • MicrocystinsDrugs and Chemicals
  • NisinDrugs and Chemicals
  • OctreotideDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

2,729
PubMed records on this heading
6%
published since 2020
96
review articles
94
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • ColistinDrugs and Chemicals
  • CyclosporineDrugs and Chemicals
  • GramicidinDrugs and Chemicals
  • MicrocystinsDrugs and Chemicals
  • NisinDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support